Literature DB >> 21744428

Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.

Christian Jakobsen1, Pia Munkholm, Anders Paerregaard, Vibeke Wewer.   

Abstract

BACKGROUND: The aim was to investigate the impact of systemic steroid treatment (SST) and immunomodulators (IM) on disease course in children with inflammatory bowel disease (IBD).
METHODS: All IBD patients in eastern Denmark <15 years of age diagnosed in the period 1998-2006 starting their first SST within 2 years of diagnosis were included.
RESULTS: In all, 205 IBD patients were included (105 Crohn's disease [CD], 100 ulcerative colitis [UC]). Eighty-seven CD (83%) and 77 (77%) UC patients started SST. In CD, 55 (63%), 25 (29%), and 7 (8%) had a complete response (CR), partial response (PR), or no response (NR), respectively, 30 days after initiation of SST. Fifty (58%) had a prolonged response (PRO) and 32 (37%) were steroid-dependent (SD). In UC, 49 (64%), 22 (28%), and 6 (8%) had CR, PR, and NR, respectively, and 38 (49%) and 38 (49%) were PRO and SD. The cumulative risk of surgery 1 year after starting SST was 11.5% and 7.8% for CD and UC patients, respectively. After a median follow-up period of 5.1 years, no difference in the risk of surgery or periods of activity and remission was found between PRO and SD in CD or UC. IM use was associated with a milder disease course in UC patients.
CONCLUSIONS: No difference in surgery rates or disease course was found between SD and PRO. Surgery rates were lower than rates from studies predating the era of IM, indicating a putative effect of IM on disease course.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21744428     DOI: 10.1002/ibd.21559

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.

Authors:  Jason M Shapiro; Sarah E Hagin; Samir A Shah; Renee Bright; Meaghan Law; Heather Moniz; Julie Giacalone; Taylor Jackvony; Sasha Taleban; Zahid Samad; Marjorie Merrick; Bruce E Sands; Neal S LeLeiko
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

Review 2.  Steroid use and misuse: a key performance indicator in the management of IBD.

Authors:  Jonathan Blackwell; Christian Selinger; Tim Raine; Gareth Parkes; Melissa A Smith; Richard Pollok
Journal:  Frontline Gastroenterol       Date:  2020-04-02

3.  Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population.

Authors:  A N Desmond; F Shanahan
Journal:  Ir J Med Sci       Date:  2011-09-24       Impact factor: 2.089

4.  Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis.

Authors:  Gayetri Deva Rajoo; Lian Tan; Ainslie Lopez; Peter Lewindon; Zubin Grover
Journal:  Dig Dis Sci       Date:  2019-02-07       Impact factor: 3.487

Review 5.  Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.

Authors:  Anastasia Konidari; Antonios Anagnostopoulos; Laura J Bonnett; Munir Pirmohamed; Wael El-Matary
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  Trends in early outpatient drug therapy in pediatric inflammatory bowel disease in Finland: a nationwide register-based study in 1999-2009.

Authors:  Lauri J Virta; Kaija-Leena Kolho
Journal:  ISRN Gastroenterol       Date:  2012-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.